Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension

 
• By Alaric DeArment

Ampreloxetine failed in a Phase III trial in 2021, but the company will start a registrational trial by the end of Q1 for the drug in the multiple system atrophy population, where it has shown efficacy.

Theravance announced its fourth quarter and full year 2022 earnings • Source: Shutterstock

More from Earnings

More from Business